Ben Machielse

Ben Machielse is the current Chairman at Polyneuron Pharmaceuticals. Ben has also served as Interim Executive Vice President, CMC at NOVAVAX INC from June 2020 to December 2020. Prior to that, they were a Member Board Of Directors at Complexa Inc. from October 2018 to August 2020.

At Complexa Inc., they were responsible for leading worldwide Manufacturing of Therapeutic Antibodies, Small Molecules and Vaccines products. Ben also oversaw QA, QC, GxP Compliance, Validation, Supply Chain, Health & Safety, Government Contracting and Engineering and Facilities in support of organization’s pipeline and commercial products. Additionally, they were a member of the Executive Team responsible for the development and execution of the corporate strategy.

During their time at Complexa Inc., they achieved many notable accomplishments such as:

-Managing and leading the development of the first H1N1 vaccine available to US public from clinical development through approval and supply.

-Leading the design, construction and start up of a new 15,000 liter bioreactor facility.

-Developing a comprehensive employee development program resulting in high employee engagement and a scalable approach towards ensuring continuous capability development.

-Achieving significant reductions in COGS through process improvements, organizational adjustments and streamlining the operations.

-Sponsoring the development and deployment of the company's first Lean/Six-Sigma strategy.

-Sponsoring the

Ben Machielse completed a Master's degree in Biochemistry and Medical Biology at Utrecht University.